Inlyta 5 mg Tablets

Inlyta 5 mg tablets contain the active ingredient Axitinib, a targeted cancer therapy classified as a tyrosine kinase inhibitor (TKI). It works by blocking vascular endothelial growth factor (VEGF) receptors, which helps prevent the formation of blood vessels that supply tumors, thereby slowing tumor growth.

Inlyta is primarily used for the treatment of advanced renal cell carcinoma (RCC).

---

Indications

Inlyta 5 mg is indicated for:

• Treatment of advanced renal cell carcinoma (RCC).

• Patients who have failed prior systemic therapy.

---

Dosage and Administration

• The recommended starting dose is 5 mg taken orally twice daily.

• Tablets can be taken with or without food.

• The dose may be adjusted by the physician based on patient tolerance and treatment response.

• Doses should be taken approximately 12 hours apart.

---

Warnings and Precautions

Consult a healthcare professional before using this medication if you have:

• High blood pressure

• Liver disease

• Bleeding disorders

• Thyroid disorders

Blood pressure and liver function should be regularly monitored during treatment.

This medication may harm an unborn baby, therefore effective contraception is recommended during treatment.

---

Possible Side Effects

Common side effects may include:

• Hypertension

• Diarrhea

• Fatigue

• Loss of appetite

• Nausea

• Hoarseness

• Hand-foot syndrome

Seek immediate medical attention if serious symptoms occur such as severe bleeding, chest pain, or difficulty breathing.